Celltrion Remsima

South Korea’s biosimilar drugmaker Celltrion group on Monday moved one step closer to the planned combination of its three major affiliates wi...

South Korea's Celltrion Inc. announced on Monday it received a new drug approval for an autoimmune disease treatment Remsima SC (active ingredient i...

South Korea's Celltrion Healthcare Co. announced on Wednesday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for ho...

South Korea's Celltrion Healthcare Co. has inked a deal with the US specialty pharmacy chain CarePartners Pharmacy to supply its autoimmune disease ...

South Korean drug giant Celltrion Group has received a positive recommendation from Institutional Shareholder Services (ISS), a global leading proxy...

Celltrion Pharm Inc. announced on Wednesday that its pre-filled syringe (PFS) production facility in Cheongju, North Chungcheong Province has obtain...

South Korea's biopharmaceutical company Celltrion Inc. announced on Tuesday that it has secured approval from the Japanese Ministry of Health, Labou...

Celltrion Inc., a South Korean biopharmaceutical giant, said Monday it will provide biosimilars worth 423.6 billion won ($323.6 million), its larges...

South Korea's Celltrion Healthcare Co. announced on Monday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatm...

The use of data and computing is a new paradigm in the biopharmaceutical industry, reducing the new drug development time and cost, Celltrion Inc. C...

South Korean biopharmaceutical firm Celltrion Inc. announced on Tuesday that it plans to enlarge its finished pharmaceuticals manufacturing facility...

South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it has completed a patent agreement with Johnson & Johnson, the m...

South Korean drug giant Celltrion Group will consider listing its holding company if necessary, after it completes the merger of three affiliates &n...

South Korea’s Celltrion Healthcare Co. announced on Wednesday that it has signed contracts with 10 insurance providers in the US to boost the ...

South Korean biopharmaceutical company Celltrion Inc. announced on Tuesday that it has received approval from the European Medicines Agency (EMA) fo...

South Korean pharmaceutical giant Celltrion Group has begun procedures to merge biopharmaceuticals developer and producer Celltrion Inc. with global...

South Korea’s No. 1 biopharmaceutical company Samsung BioLogics Co. and No. 2 Celltrion Inc. produced higher CO2 emissions last year than in 2...

South Korean biopharmaceutical company Celltrion Healthcare on Monday said it launched the day before on the US market Yuflyma, a biosimilar of the ...

South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P...

South Korea’s Celltrion Inc. has put its Japanese Takeda Pharmaceutical Co.'s primary care assets acquired in 2020 on sale as the biosimilar g...

South Korea's biopharmaceutical company Celltrion Inc. announced that it received on Thursday approval from the US Food and Drug Administration (FDA...

South Korea's biopharmaceutical company Celltrion Inc. announced on Tuesday that it plans to beef up its portfolio by applying for regulatory approv...

South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics ...

MILAN – South Korea's biopharmaceutical company Celltrion Inc. is known in Europe for its biosimilar products such as autoimmune disease treat...

South Korean biosimilar giant Celltrion Inc. revealed on Wednesday the highly anticipated clinical phase 1 data for its Actemra biosimilar, CT-P47, ...

More than 500 South Korean companies from top business groups to AI-based biotech startups are slated to attend the Bio International Convention 202...

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Adminis...

South Korean biopharmaceutical company Celltrion Healthcare Co. revealed on Monday its introduction of Remsima SC, a treatment for autoimmune diseas...

Celltrion Inc. announced on Tuesday it has decided not to pursue the acquisition of the biopharmaceutical unit of U.S. medical device maker Baxter I...

South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...